Nagdeep Giri Selected Research

dacomitinib

1/2020	Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer.
10/2017	Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.
3/2017	A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors.
1/2017	Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
1/2015	Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
10/2014	Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
5/2014	A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nagdeep Giri Research Topics

Disease

5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 05/2014
3	Breast Neoplasms (Breast Cancer) 03/2009 - 07/2007
2	Diarrhea 10/2017 - 01/2017
2	Lung Neoplasms (Lung Cancer) 10/2017 - 01/2015
2	Stomatitis 10/2017 - 01/2017
1	Congenital adrenal hyperplasia due to 21 hydroxylase deficiency 01/2022
1	Congenital Adrenal Hyperplasia (Hyperplasia, Congenital Adrenal) 01/2022
1	Paronychia 10/2017
1	Fatigue 10/2017
1	Exanthema (Rash) 10/2017
1	Nausea 10/2017
1	Adenoid Cystic Carcinoma (Cylindroma) 03/2017
1	Neoplasms (Cancer) 03/2017
1	Liver Diseases (Liver Disease) 01/2015
1	Disease Progression 10/2014
1	Adenocarcinoma 10/2014

Drug/Important Bio-Agent (IBA)

7	dacomitinibIBA 01/2020 - 05/2014
3	ErbB Receptors (EGF Receptor)IBA 01/2020 - 10/2014
3	Proteins (Proteins, Gene)FDA Link 03/2009 - 07/2007
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 10/2014
1	crinecerfontIBA 01/2022
1	AndrogensIBA 01/2022
1	Hormones (Hormone)IBA 01/2022
1	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2022
1	Somatomedin Receptors (Somatomedin Receptor)IBA 03/2017
1	figitumumabIBA 03/2017
1	Epidermal Growth Factor (EGF)IBA 01/2015
1	Phosphotransferases (Kinase)IBA 01/2015
1	Tyrosine (L-Tyrosine)FDA Link 01/2015
1	Blood Proteins (Serum Proteins)IBA 01/2015
1	Gefitinib (Iressa)FDA Link 10/2014
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2014
1	Carrier Proteins (Binding Protein)IBA 08/2008
1	abacavir (Ziagen)FDA Link 08/2008
1	Zidovudine (Retrovir)FDA LinkGeneric 08/2008
1	NucleosidesIBA 07/2007
1	Reverse Transcriptase InhibitorsIBA 07/2007

Therapy/Procedure

1	Therapeutics 03/2017
1	Drug Therapy (Chemotherapy) 10/2014